Skip to main content

topiramate

Generic: TOPIRAMATE·Brand: EPRONTIA, Eprontia, QUDEXY XR, Qsymia, Qudexy, TOPAMAX, TOPAMAX SPRINKLE, TOPIRAMATE, TROKENDI XR, Topamax, Trokendi

topiramate: developed by 1 company · 4 clinical trials tracked.

topiramate evidence translation

What we can confirm

What it means

Source-backed records connect topiramate to SUPN; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could topiramate → SUPN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 3 study sponsors

Related indications

Epilepsy: initial monotherapy for partial-onset and primary generalized tonic-clonic seizures in patients 6 years and older; adjunctive therapy for certain seizures including those associated with Lennox-Gastaut Syndrome in patients 6 years and older; preventive treatment of migraine in patients 12 years and olderMigraineObesity
Development Pipeline (1)
CompanyPhase
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Epilepsy: initial monotherapy for partial-onset and primary …
Approved
Clinical Trials (4)

A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study

NCT06972056·Phase 4
Recruiting

Primary endpoint: Treatment Responder (atogepant vs. topiramate; atogepant vs. propranolol)

InterventionalRandomizedopen1,335 targetStarted 2025-07Completion 2029-1236 sites · United StatesMayo Clinic

A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)

NCT05748483·Phase 3·ABBV
Completed

Primary endpoint: Percentage of Participants Who Discontinued Treatment Due to Treatment-Emergent Adverse Events (TEAEs)

InterventionalRandomizedquadruple545 enrolledStarted 2023-10Completion 2026-0650 sites · Austria, Belgium, Canada, Czechia…AbbVie

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

NCT05579249·Phase 4·NVO
Completed

Primary endpoint: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

InterventionalRandomizedopen500 enrolledStarted 2023-01Completion 2024-111 site · United StatesNovo Nordisk A/S

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University

Frequently asked questions

Who is developing topiramate?

topiramate is being developed by SUPERNUS PHARMACEUTICALS, INC..

How many clinical trials involve topiramate?

BioSniper tracks 4 clinical trials involving topiramate.